First treatment to tackle protein behind the disease wins approval — but only a small fraction of patients will benefit.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted therapies to improve CFTR function in cystic fibrosis
Genome Medicine Open Access 24 September 2015
-
Saliva as a potential tool for cystic fibrosis diagnosis
Diagnostic Pathology Open Access 19 March 2013
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Charities seek cut of drug royalties 2011-Jul-20
Growth factor makes a comeback in cystic fibrosis 2010-Nov-08
Human genome at ten: Life is complicated 2010-Mar-31
Human genetics: One gene, twenty years 2009-Jul-08
Drug makes cells ignore mutation 2006-Nov-09
Blogpost: US approves landmark cystic fibrosis drug
Related external links
Rights and permissions
About this article
Cite this article
Ledford, H. Drug bests cystic-fibrosis mutation. Nature 482, 145 (2012). https://doi.org/10.1038/482145a
Published:
Issue date:
DOI: https://doi.org/10.1038/482145a
This article is cited by
-
The virtuous cycle of human genetics and mouse models in drug discovery
Nature Reviews Drug Discovery (2019)
-
Targeted therapies to improve CFTR function in cystic fibrosis
Genome Medicine (2015)
-
Saliva as a potential tool for cystic fibrosis diagnosis
Diagnostic Pathology (2013)
-
Longitudinal Cystic Fibrosis Care
Clinical Pharmacology & Therapeutics (2013)
